Healthcare / Drug Manufacturers - Specialty & GenericBSE
$1.81
+0.03 (+1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-25.1M · quality 29.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$72M
P/E
18.1x
↓EV/EBITDA
20.6x
↑ROE
9.0%
↑Gross Margin
1.3%
↓Debt/Equity
2.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+86.7%
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
-6.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.16B · net income $3.9M · FCF $-27.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.16B | $1.16B | $74.2M | $278.4M | $178.1M |
| Net Income | $3.9M | $3.9M | $-6.7M | $5.5M | $6.0M |
| EBITDA | $8.4M | $8.4M | $-3.0M | $11.2M | $11.4M |
| EPS | — | — | -0.17 | 0.01 | 0.15 |
| Gross Margin | 1.3% | 1.3% | 8.1% | 6.8% | 7.3% |
| Operating Margin | 0.6% | 0.6% | -5.1% | 3.9% | 4.1% |
| Net Margin | 0.3% | 0.3% | -9.1% | 2.0% | 3.4% |
| Balance Sheet | |||||
| Debt/Equity | 2.34 | 2.34 | 2.18 | 1.11 | 1.95 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.0M | $-27.0M | $-25.1M | $20.1M | $-9.5M |
| Returns | |||||
| ROE | 9.0% | 9.0% | -17.0% | 11.8% | 14.6% |
| Valuation | |||||
| P/E | 18.10 | 18.10 | — | 577.86 | 119.07 |
| EV/EBITDA | 20.56 | 20.56 | — | 33.35 | 69.70 |
| P/B | 1.66 | 1.66 | 2.39 | 6.98 | 17.46 |
| Growth & Yield | |||||
| Revenue Growth | 1461.4% | 1461.4% | -73.3% | 56.3% | — |
| EPS Growth | — | — | -1314.3% | -90.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → n/d
Residual
-23.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.